D'Orazio & Associates’s Vir Biotechnology VIR Stock Holding History

D'Orazio & Associates’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	684
2021 Q3	$0	Hold	1	–	–	﹤0.01%	787
2021 Q2	$0	Hold	1	–	–	﹤0.01%	424
2021 Q1	$0	Hold	1	–	–	﹤0.01%	421
2020 Q4	$0	Hold	1	–	–	﹤0.01%	374
2020 Q3	$0	Hold	1	–	–	﹤0.01%	360
2020 Q2	$0	Buy	+1	New	+$34	﹤0.01%	363

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

D'Orazio & Associates's VIR Position: Q4 2021 in Review

D'Orazio & Associates sold out of Vir Biotechnology (VIR) in Q4 2021, closing a stake of 1 share.

D'Orazio & Associates first reported a position in VIR in Q2 2020 and held it in 6 quarters. The position peaked at $0 in Q3 2021. 210 funds tracked by Wall St. Rank hold VIR as of Q4 2021.

D'Orazio & Associates reported no remaining Vir Biotechnology position as of Q4 2021 after selling out during the quarter.
D'Orazio & Associates sold 1 Vir Biotechnology share in Q4 2021.
D'Orazio & Associates first reported a position in Vir Biotechnology in Q2 2020 and held it in 6 quarters.
D'Orazio & Associates's Vir Biotechnology position peaked at $0 in Q3 2021.
210 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2021.

Based on D'Orazio & Associates's 13F filing for Q4 2021, filed 7 Feb 2022.